RAPT Operating Income vs Total Operating Expenses Analysis

RAPT Stock

USD 1.08 0.03 2.86%

RAPT Therapeutics financial indicator trend analysis is much more than just breaking down RAPT Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RAPT Therapeutics is a good investment. Please check the relationship between RAPT Therapeutics Operating Income and its Total Operating Expenses accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

Operating Income vs Total Operating Expenses

Operating Income vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RAPT Therapeutics Operating Income account and Total Operating Expenses. At this time, the significance of the direction appears to have pay attention.

The correlation between RAPT Therapeutics' Operating Income and Total Operating Expenses is -0.93. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of RAPT Therapeutics, assuming nothing else is changed. The correlation between historical values of RAPT Therapeutics' Operating Income and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of RAPT Therapeutics are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Operating Income i.e., RAPT Therapeutics' Operating Income and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.93

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from RAPT Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of RAPT Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from RAPT Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RAPT Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.At this time, RAPT Therapeutics' Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 12.53 in 2024, whereas Selling General Administrative is likely to drop slightly above 14.6 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	996K	1.0M	1.1M	944.2K
Total Operating Expenses	73.0M	87.3M	127.1M	71.6M

Reconciled Depreciation Total Operating Expenses

RAPT Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital
Total Assets		0.72	0.81	0.95	0.84	0.89	0.84	0.57	-0.85	0.77	-0.45	0.91	0.9	0.78	1.0	0.91	0.9	-0.75	0.89	0.67	0.95	-0.72	0.95	0.62	1.0	1.0
Other Current Liab	0.72		0.82	0.69	0.7	0.89	0.68	0.5	-0.95	0.86	-0.48	0.74	0.9	0.18	0.71	0.78	0.84	-0.62	0.92	0.52	0.82	-0.56	0.69	0.92	0.71	0.69
Total Current Liabilities	0.81	0.82		0.84	0.91	0.91	0.84	0.36	-0.92	0.95	-0.24	0.87	0.82	0.31	0.8	0.91	0.98	-0.78	0.91	0.62	0.93	-0.73	0.84	0.81	0.8	0.77
Total Stockholder Equity	0.95	0.69	0.84		0.89	0.87	0.82	0.41	-0.84	0.76	-0.31	0.86	0.83	0.68	0.95	0.96	0.91	-0.92	0.87	0.76	0.95	-0.9	1.0	0.62	0.95	0.94
Other Liab	0.84	0.7	0.91	0.89		0.89	0.68	0.47	-0.83	0.78	-0.39	0.73	0.72	0.45	0.83	0.89	0.92	-0.85	0.87	0.87	0.9	-0.82	0.89	0.59	0.84	0.81
Net Tangible Assets	0.89	0.89	0.91	0.87	0.89		0.78	0.46	-0.97	0.83	-0.4	0.84	0.93	0.44	0.89	0.89	0.95	-0.76	1.0	0.69	0.92	-0.72	0.87	0.83	0.89	0.87
Property Plant And Equipment Net	0.84	0.68	0.84	0.82	0.68	0.78		0.22	-0.82	0.86	-0.06	0.98	0.83	0.52	0.83	0.83	0.87	-0.69	0.8	0.34	0.87	-0.66	0.82	0.77	0.83	0.81
Net Debt	0.57	0.5	0.36	0.41	0.47	0.46	0.22		-0.42	0.42	-0.97	0.34	0.47	0.5	0.58	0.36	0.42	-0.15	0.45	0.58	0.51	-0.12	0.41	0.18	0.58	0.59
Retained Earnings	-0.85	-0.95	-0.92	-0.84	-0.83	-0.97	-0.82	-0.42		-0.9	0.35	-0.87	-0.95	-0.35	-0.84	-0.9	-0.95	0.75	-0.99	-0.59	-0.92	0.7	-0.84	-0.92	-0.84	-0.82
Accounts Payable	0.77	0.86	0.95	0.76	0.78	0.83	0.86	0.42	-0.9		-0.28	0.89	0.83	0.28	0.76	0.86	0.93	-0.67	0.85	0.46	0.91	-0.61	0.76	0.84	0.76	0.73
Cash	-0.45	-0.48	-0.24	-0.31	-0.39	-0.4	-0.06	-0.97	0.35	-0.28		-0.18	-0.39	-0.38	-0.47	-0.26	-0.3	0.1	-0.39	-0.59	-0.39	0.07	-0.31	-0.13	-0.47	-0.48
Non Current Assets Total	0.91	0.74	0.87	0.86	0.73	0.84	0.98	0.34	-0.87	0.89	-0.18		0.9	0.59	0.9	0.89	0.92	-0.69	0.86	0.4	0.93	-0.65	0.86	0.78	0.9	0.88
Non Currrent Assets Other	0.9	0.9	0.82	0.83	0.72	0.93	0.83	0.47	-0.95	0.83	-0.39	0.9		0.53	0.9	0.87	0.9	-0.65	0.95	0.48	0.9	-0.6	0.83	0.86	0.9	0.88
Other Assets	0.78	0.18	0.31	0.68	0.45	0.44	0.52	0.5	-0.35	0.28	-0.38	0.59	0.53		0.79	0.54	0.46	-0.4	0.42	0.42	0.59	-0.41	0.68	0.06	0.79	0.81
Cash And Short Term Investments	1.0	0.71	0.8	0.95	0.83	0.89	0.83	0.58	-0.84	0.76	-0.47	0.9	0.9	0.79		0.9	0.89	-0.74	0.88	0.67	0.95	-0.71	0.95	0.61	1.0	1.0
Common Stock Total Equity	0.91	0.78	0.91	0.96	0.89	0.89	0.83	0.36	-0.9	0.86	-0.26	0.89	0.87	0.54	0.9		0.96	-0.89	0.9	0.68	0.98	-0.87	0.96	0.72	0.9	0.88
Common Stock Shares Outstanding	0.9	0.84	0.98	0.91	0.92	0.95	0.87	0.42	-0.95	0.93	-0.3	0.92	0.9	0.46	0.89	0.96		-0.81	0.95	0.65	0.98	-0.77	0.91	0.8	0.9	0.87
Non Current Liabilities Total	-0.75	-0.62	-0.78	-0.92	-0.85	-0.76	-0.69	-0.15	0.75	-0.67	0.1	-0.69	-0.65	-0.4	-0.74	-0.89	-0.81		-0.77	-0.76	-0.82	1.0	-0.92	-0.59	-0.75	-0.73
Capital Surpluse	0.89	0.92	0.91	0.87	0.87	1.0	0.8	0.45	-0.99	0.85	-0.39	0.86	0.95	0.42	0.88	0.9	0.95	-0.77		0.66	0.93	-0.72	0.87	0.87	0.88	0.86
Other Current Assets	0.67	0.52	0.62	0.76	0.87	0.69	0.34	0.58	-0.59	0.46	-0.59	0.4	0.48	0.42	0.67	0.68	0.65	-0.76	0.66		0.68	-0.76	0.76	0.3	0.68	0.67
Other Stockholder Equity	0.95	0.82	0.93	0.95	0.9	0.92	0.87	0.51	-0.92	0.91	-0.39	0.93	0.9	0.59	0.95	0.98	0.98	-0.82	0.93	0.68		-0.79	0.95	0.74	0.95	0.93
Total Liab	-0.72	-0.56	-0.73	-0.9	-0.82	-0.72	-0.66	-0.12	0.7	-0.61	0.07	-0.65	-0.6	-0.41	-0.71	-0.87	-0.77	1.0	-0.72	-0.76	-0.79		-0.9	-0.53	-0.72	-0.7
Net Invested Capital	0.95	0.69	0.84	1.0	0.89	0.87	0.82	0.41	-0.84	0.76	-0.31	0.86	0.83	0.68	0.95	0.96	0.91	-0.92	0.87	0.76	0.95	-0.9		0.62	0.95	0.94
Property Plant And Equipment Gross	0.62	0.92	0.81	0.62	0.59	0.83	0.77	0.18	-0.92	0.84	-0.13	0.78	0.86	0.06	0.61	0.72	0.8	-0.59	0.87	0.3	0.74	-0.53	0.62		0.61	0.58
Total Current Assets	1.0	0.71	0.8	0.95	0.84	0.89	0.83	0.58	-0.84	0.76	-0.47	0.9	0.9	0.79	1.0	0.9	0.9	-0.75	0.88	0.68	0.95	-0.72	0.95	0.61		1.0
Net Working Capital	1.0	0.69	0.77	0.94	0.81	0.87	0.81	0.59	-0.82	0.73	-0.48	0.88	0.88	0.81	1.0	0.88	0.87	-0.73	0.86	0.67	0.93	-0.7	0.94	0.58	1.0

Click cells to compare fundamentals

RAPT Therapeutics Account Relationship Matchups

RAPT Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	84.6M	119.0M	198.6M	266.2M	173.3M	151.1M
Other Current Liab	471K	5.3M	6.6M	6.5M	11.8M	12.4M
Total Current Liabilities	9.3M	11.7M	9.6M	14.2M	21.8M	11.7M
Total Stockholder Equity	73.1M	104.2M	186.4M	245.2M	147.0M	119.0M
Other Liab	969K	2.2M	3.0M	2.7M	3.1M	2.2M
Net Tangible Assets	73.1M	104.2M	186.4M	245.2M	281.9M	296.0M
Property Plant And Equipment Net	3.7M	3.0M	2.7M	9.5M	7.7M	5.1M
Net Debt	(77.4M)	(24.9M)	(24.0M)	(30.0M)	(40.6M)	(42.6M)
Retained Earnings	(162.0M)	(214.8M)	(284.0M)	(367.9M)	(484.7M)	(460.4M)
Accounts Payable	1.1M	2.4M	2.0M	3.4M	5.2M	2.7M
Cash	77.4M	24.9M	24.0M	38.9M	47.5M	37.0M
Non Current Assets Total	4.1M	3.4M	5.7M	13.5M	11.5M	7.1M
Cash And Short Term Investments	77.4M	111.5M	189.7M	249.1M	158.9M	141.1M
Common Stock Shares Outstanding	21.8M	24.1M	27.4M	32.5M	38.3M	27.7M
Liabilities And Stockholders Equity	84.6M	119.0M	198.6M	266.2M	173.3M	151.1M
Non Current Liabilities Total	2.2M	3.0M	2.7M	6.8M	4.5M	4.2M
Capital Surpluse	235.0M	319.2M	470.6M	613.1M	705.0M	740.3M
Other Current Assets	3.1M	8.2M	6.6M	3.6M	2.9M	4.2M
Other Stockholder Equity	150.4M	319.2M	470.6M	613.1M	631.6M	375.9M
Total Liab	11.5M	14.8M	12.3M	21.0M	26.3M	23.3M
Net Invested Capital	73.1M	104.2M	186.4M	245.2M	147.0M	119.0M
Property Plant And Equipment Gross	3.7M	3.0M	2.7M	9.5M	17.0M	17.9M
Total Current Assets	80.5M	115.6M	193.0M	252.7M	161.8M	144.1M
Accumulated Other Comprehensive Income	20K	(177K)	(206K)	(26K)	103K	108.2K
Net Working Capital	71.3M	103.9M	183.4M	238.5M	139.9M	132.4M
Property Plant Equipment	3.7M	3.0M	2.7M	2.5M	2.3M	2.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC